← All candidates
53 insider filings on record.
53 filings on record.
MGNXMACROGENICS INC
NasdaqGS · Healthcare · $263.72M
$4.14
+0.24% · Sep 18
53 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 1 sell◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$263.72M
Float
56.4M
89% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
1.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Heiden William K
Bought $76.8K on Aug 19 — 50,500 sh @ $1.52, held direct, 82% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
48 more transactions on Pro →Context
Wall St
$8.00 avg target
+93.2% vs today · 4 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q2 '26$1.14 act+$0.88
Q1 '26−$0.58 act−$0.03
Q4 '25−$0.22 act−$0.20
Q3 '25$0.27 act+$0.78
Coverage
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Zacks · 08-20Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?Insider Monkey · 08-15MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue EstimatesZacks · 08-13MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?Zacks · 07-02
The file stays open
53 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice